Fig. 2From: Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradicationThe Helicobacter pylori eradication rates in susceptibility-guided therapy and empirical therapy. The p-values for superiority in susceptibility-guided proton pump inhibitor-based triple therapy are provided. PPI proton pump inhibitorBack to article page